This issue includes a report of a case of MET-amplified neuroendocrine cancer detected by gene panel testing that responded to capmatinib [1]. Capmatinib is approved by the Food and Drug Administration for non-small cell lung cancer with MET exon 14 skipping. However, capmatinib is not approved for MET amplification. Capmatinib was given to this patient under the Patient Application for Multiple Molecularly Targeted Therapies Based on Gene Profiling by Gene Panel Testing programme (jRCTs031190104) [2]. This case report is a good example of the discovery of a novel molecularly targeted therapy based on gene panel testing.
Data availability
This article contains all the data needed to create this article.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Yamamura S, Kanai M, Takeuchi Y, et al. Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification. Int Canc Conf J. 2024 doi: 10.1007/s13691-023-00643-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.https://ct.ganjoho.jp/category/ttrial/jRCTs031190104. Accessed Mar 6 2024
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
This article contains all the data needed to create this article.